You are here: Industry Insights > AbbVie

News List

AbbVie and Mission partner on Alzheimer’s and Parkinson’s drugs pharmaceutical-technology
November 20, 2018
AbbVie has collaborated with UK-based drug discovery firm Mission Therapeutics for research and preclinical development of potential therapies to treat Alzheimer’s disease and Parkinson’s disease.
Samsung Bioepis’ biosimilar to Humira launched in the EU pharmaceutical
November 19, 2018
ImraldiHumira, which is admistered by injection, has lost its exclusive patent in the EU, leading to the launch of biosimilars, including Samsung Bioepis' Imraldi. Credit: Pixabay.
Mission links with AbbVie to develop Alzheimer’s, Parkinson’s therapies pharmatimes
November 19, 2018
UK drug discovery and development group Mission Therapeutics has signed a deal with AbbVie focusing on early stage development of specified DUB inhibitors for the
AbbVie's Orilissa makes its uterine fibroids case with double phase 3 win fiercepharma
November 16, 2018
AbbVie’s Orilissa (elagolix) snagged its first FDA approval over the summer, and now it’s looking to make it two.
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries fiercepharma
November 14, 2018
AbbVie has had success with its new pan-genotypic hepatitis C drug Mavyret, generating blockbuster-level sales at the expense of competitors.
AbbVie announces global patent license with Momenta biospectrum
November 08, 2018
Momenta's U.S. license will begin on November 20, 2023, and will not be accelerated by the entry of companies who have already taken a license.
AbbVie's 96% tax break: Big Pharma reaps huge benefit from Trump tax reform fiercepharma
November 05, 2018
AbbVie is known as one of the largest pharma beneficiaries of the U.S. tax reform. Just how much has it gained? In the first nine months of 2018, the Illinois pharma has paid just 4.5% of the income taxes it shelled out the same period last year.
AbbVie offers up 80% Humira discount in EU tender market to hold off biosimilars: report fiercepharma
November 02, 2018
How far is AbbVie willing to go to fend off the new Humira biosimilars in Europe? Quite far, apparently, judging by the enormous discount it offered to win a government contract.
AbbVie assumes full development and commercial control of CF programme pharmatimes
November 01, 2018
AbbVie has announced that it will assume full development and commercial responsibility for its collaboration with Galapagos to discover and develop new therapies to treat cystic fibrosis (CF).
AbbVie’s Venclyxto hit with NICE rejection pharmatimes
November 01, 2018
Draft guidelines do not recommend NHS use of AbbVie’s Venclyxto for treating relapsed or refractory chronic lymphocytic leukaemia (CLL).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page